Lift in Interest, page-22

If the Company's reports have any credibility, some results from the Lupus trial are well overdue. The trial is in four cohorts and I would have thought we should expect a result from each individual cohort. If the whole trial (four cohorts) is to be completed by end 2014 one would have thought that two or three cohorts should have completed by now. If the targets are not being met we should be told. Recruitment is always a problem with these trials but shareholders should be kept informed about problems. It is unfair to just say nothing when promised reports are long overdue.